Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 18/20 | 0.74 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.34 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20164850 | 0.85 | AAK1 (1.00) | AAK1 | |
| SCHEMBL20164851 | 0.85 | AAK1 (1.00) | AAK1 | |
| SCHEMBL21018885 | 0.84 | AAK1 (0.61) | AAK1DYRK1A | |
| SCHEMBL19946128 | 0.83 | AAK1 (0.84) | AAK1 | |
| SCHEMBL19946055 | 0.78 | AAK1 (0.66) | AAK1DYRK1AHASPINDYRK2 | |
| SCHEMBL19946065 | 0.77 | AAK1 (0.67) | AAK1 | |
| SCHEMBL20176314 | 0.76 | AAK1 (0.71) | AAK1 | |
| SCHEMBL21019093 | 0.76 | AAK1 (0.66) | AAK1DYRK1AHASPINDYRK2 | |
| SCHEMBL20181535 | 0.76 | AAK1 (0.79) | AAK1 | |
| SCHEMBL21018869 | 0.75 | AAK1 (0.53) | AAK1DYRK1AHASPINDYRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10174044-B2 | Fused pyridines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180141956-A1 | FUSED PYRIDINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10174044-B2 | Fused pyridines as kinase inhibitors | AAK1, NCK1, ADCK1 | AAK1 1/4885DYRK1A 518/4885HASPIN 734/4885 |
| US-20180141956-A1 | FUSED PYRIDINES AS KINASE INHIBITORS | AAK1, NCK1, ADCK1 | AAK1 1/4885DYRK1A 518/4885HASPIN 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.